← Back to headlines
Disappointing trial results impact Regeneron Pharmaceuticals in Q2
Regeneron Pharmaceuticals (REGN) experienced a setback in its second quarter due to disappointing results from recent clinical trials, affecting its financial performance.
13 Jul, 14:33 — 13 Jul, 14:33
Sources
Showing 1 of 1 sources
